{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:54:03Z","timestamp":1763348043012},"reference-count":43,"publisher":"Impact Journals, LLC","issue":"44","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,11,1]]},"DOI":"10.18632\/oncotarget.12291","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T22:40:28Z","timestamp":1475016028000},"page":"72099-72112","source":"Crossref","is-referenced-by-count":17,"title":["Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm"],"prefix":"10.18632","volume":"7","author":[{"given":"Cheol Keun","family":"Park","sequence":"first","affiliation":[{"name":"Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Soo","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Yonsei Cancer Center, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyo Song","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Yonsei Cancer Center, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sun Young","family":"Rha","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Yonsei Cancer Center, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Jin","family":"Hyung","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Ho","family":"Cheong","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung Hoon","family":"Noh","sequence":"additional","affiliation":[{"name":"Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Kil","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Chan","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-min","family":"Huh","sequence":"additional","affiliation":[{"name":"YUMS-KRIBB Medical Convergence Research Institute, Department of Radiology, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunki","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,9,27]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Bray","year":"2015","journal-title":"Int J Cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.5009\/gnl.2013.7.4.385","article-title":"Chemotherapy for advanced gastric cancer: review and update of current practices","volume":"7","author":"Chun","year":"2013","journal-title":"Gut Liver"},{"key":"3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1586\/egh.11.103","article-title":"Management of advanced gastric cancer","volume":"6","author":"Tebbutt","year":"2012","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Kang","year":"2010","journal-title":"Lancet"},{"key":"5","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1007\/s10637-011-9699-0","article-title":"Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks","volume":"30","author":"Minami","year":"2012","journal-title":"Invest New Drugs"},{"key":"6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1756283X12453636","article-title":"Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?","volume":"6","author":"Yau","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"key":"7","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2013.53.6136","article-title":"Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study","volume":"32","author":"Bang","year":"2014","journal-title":"J Clin Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s10120-014-0420-9","article-title":"Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer","volume":"18","author":"Sakata","year":"2015","journal-title":"Gastric Cancer"},{"key":"9","doi-asserted-by":"crossref","first-page":"e0148101","DOI":"10.1371\/journal.pone.0148101","article-title":"Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma","volume":"11","author":"Eberhard","year":"2016","journal-title":"PLoS One"},{"key":"10","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/bjc.2014.61","article-title":"HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma","volume":"110","author":"Ni","year":"2014","journal-title":"Br J Cancer"},{"key":"11","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1002\/ijc.29159","article-title":"HER2-positive gastric cancer with concomitant MET and\/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy","volume":"136","author":"Kim","year":"2015","journal-title":"Int J Cancer"},{"key":"12","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s10120-013-0288-0","article-title":"Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection","volume":"17","author":"Ahn","year":"2014","journal-title":"Gastric Cancer"},{"key":"13","first-page":"1547","article-title":"The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen","volume":"32","author":"Bang","year":"2012","journal-title":"Anticancer Res"},{"key":"14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"The Cancer Genome Atlas Research N","year":"2014","journal-title":"Nature"},{"key":"15","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00428-013-1517-y","article-title":"FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation","volume":"464","author":"Womack","year":"2014","journal-title":"Virchows Arch"},{"key":"16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10120-015-0471-6","article-title":"Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients","volume":"19","author":"Ohtsu","year":"2016","journal-title":"Gastric Cancer"},{"key":"17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.canlet.2014.07.021","article-title":"Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH","volume":"353","author":"Tan","year":"2014","journal-title":"Cancer Lett"},{"key":"18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/bjc.2014.649","article-title":"Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression","volume":"112","author":"Zhang","year":"2015","journal-title":"Br J Cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial","volume":"14","author":"Barbachano","year":"2013","journal-title":"Lancet Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/apm.12359","article-title":"Targeted therapy in gastric cancer","volume":"123","author":"Ristimaki","year":"2015","journal-title":"Apmis"},{"key":"21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nm.3850","article-title":"Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes","volume":"21","author":"Aggarwal","year":"2015","journal-title":"Nat Med"},{"key":"22","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00535-014-0984-5","article-title":"Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab","volume":"50","author":"Shoda","year":"2015","journal-title":"J Gastroenterol"},{"key":"23","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3892\/ol.2016.4198","article-title":"Genetic alterations of HER genes in chromophobe renal cell carcinoma","volume":"11","author":"Pang","year":"2016","journal-title":"Oncol Lett"},{"key":"24","first-page":"5055","article-title":"Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance","volume":"35","author":"Shimada","year":"2015","journal-title":"Anticancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"e0143207","DOI":"10.1371\/journal.pone.0143207","article-title":"Intra-Tumoral Heterogeneity of HER2, FGFR2, cMET and ATM in Gastric Cancer: Optimizing Personalized Healthcare through Innovative Pathological and Statistical Analysis","volume":"10","author":"Yin","year":"2015","journal-title":"PLoS One"},{"key":"26","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Diaz","year":"2015","journal-title":"N Engl J Med"},{"key":"27","doi-asserted-by":"publisher","first-page":"32925","DOI":"10.18632\/oncotarget.9076","article-title":"Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers","volume":"7","author":"Bass","year":"2016","journal-title":"Oncotarget"},{"key":"28","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1200\/JCO.2013.48.9070","article-title":"Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab","volume":"31","author":"Lopez-Rios","year":"2013","journal-title":"J Clin Oncol"},{"key":"29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: a practical approach","volume":"25","author":"Viale","year":"2012","journal-title":"Mod Pathol"},{"key":"30","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Henkel","year":"2008","journal-title":"Histopathology"},{"key":"31","first-page":"208","article-title":"[Her2 testing in gastric cancer. What is different in comparison to breast cancer?]","volume":"31","author":"Kreipe","year":"2010","journal-title":"Pathologe"},{"key":"32","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/modpathol.2011.85","article-title":"Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis","volume":"24","author":"Kurman","year":"2011","journal-title":"Mod Pathol"},{"key":"33","first-page":"20988","article-title":"Immunohistochemistry and microsatellite instability analysis in molecular subtyping of colorectal carcinoma based on mismatch repair competency","volume":"8","author":"Shi","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH644>3.0.CO;2-T","article-title":"Immunohistochemical detection of mismatch repair gene proteins as a useful tool for the identification of colorectal carcinoma with the mutator phenotype","volume":"191","author":"Soares","year":"2000","journal-title":"J Pathol"},{"key":"35","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1200\/JCO.2002.20.4.1043","article-title":"Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors","volume":"20","author":"Thibodeau","year":"2002","journal-title":"J Clin Oncol"},{"key":"36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00428-003-0833-z","article-title":"Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression","volume":"443","author":"Flejou","year":"2003","journal-title":"Virchows Arch"},{"key":"37","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.6004\/jnccn.2014.0099","article-title":"Colon cancer, version 3. 2014","volume":"12","author":"Freedman-Cass","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"38","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.surg.2005.08.021","article-title":"Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers","volume":"139","author":"Moore","year":"2006","journal-title":"Surgery"},{"key":"39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jso.21220","article-title":"Clinicopathologic characteristics and outcomes of gastric cancers with the MSI-H phenotype","volume":"99","author":"Lee","year":"2009","journal-title":"J Surg Oncol"},{"key":"40","doi-asserted-by":"crossref","first-page":"S772","DOI":"10.1245\/s10434-015-4794-7","article-title":"Poorly Differentiated Carcinoma Component in Submucosal Layer Should be Considered as an Additional Criterion for Curative Endoscopic Resection of Early Gastric Cancer","volume":"22","author":"Kim","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"41","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10120-011-0042-4","article-title":"Japanese gastric cancer treatment guidelines 2010 (ver. 3)","volume":"14","author":"Japanese Gastric Cancer A","year":"2011","journal-title":"Gastric Cancer"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-015-0565-1","article-title":"Epstein-Barr virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer","author":"Kim","year":"2015","journal-title":"Gastric Cancer"},{"key":"43","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.gastro.2010.04.002","article-title":"Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma","volume":"139","author":"Kim","year":"2010","journal-title":"Gastroenterology"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T13:58:13Z","timestamp":1589291893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,27]]},"references-count":43,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2016,11,1]]}},"alternative-id":["12291","27765925"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12291","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,27]]}}}